LINCOLN, R.I.--(BUSINESS WIRE)--Nov. 12, 2005--RenaMed Biologics, Inc. (RenaMed(TM)) reported today at the American Society of Nephrology preliminary positive findings from a Phase II, controlled randomized study of its Renal Bio-Replacement Therapy to treat patients with acute renal failure (ARF or acute kidney injury). The study of fifty-eight (58) patients found that RenaMed’s therapy at 28 days increased survival rate by seventy two percent (72%). This trend in improved survival was sustained through 90 and 180-days.
